Supernus Pharmaceuticals To Acquire Sage Therapeutics To Enter The Depression Market 

Supernus Pharmaceuticals, Inc. (Supernus) and Sage Therapeutics, Inc. (Sage) announced a definitive agreement for Supernus to acquire Sage for $975 million. With the deal, Supernus will acquire the rights to Sage Therapeutics’ oral treatment for postpartum depression, Zurzuvae, which it developed with Biogen. According to the announcement, Zurzuvae is the only oral medication approved by the U.S. Food and Drug Administration (FDA) to treat postpartum depression. The transaction is expected to close in the third quarter of 2025.;

In an investor presentation about the deal, Supernus stated that the U.S. Centers for Disease Control and Prevention estimates . . .